the placebo group
[용어속성] Patient
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Clinical Trial
[키워드] 95% CI
95% confidence interval
acute respiratory syndrome
adverse event
antibody cocktail
assigned
authority
average
baseline
characterized
cocktail
Complication
coronavirus
coronavirus disease
death
Department
development
dose
double-blind
end point
greater
group
Human
hypersensitivity reactions
immune response
in viral
initiated
interim analysis
investigated
log
mean difference
mutant virus
neutralizing monoclonal antibody
outcome
Outpatient
Patient
patients
percentage
Placebo
placebo group
Randomly
Reactions
receive
recent
reduce
reduced
Regeneron Pharmaceutical
REGN-CoV2
reported
risk
Safety
SARS-CoV-2
serum
Spike protein
the patient
the placebo group
Trial
Viral load
viral loads
[DOI] 10.1056/NEJMoa2035002 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1056/NEJMoa2035002 PMC 바로가기 [Article Type] Clinical Trial
Pilot trial of high-dose vitamin C in critically ill COVID-19 patients
Research
[키워드] 1:1
28-day mortality
95% CI
acute respiratory syndrome
assessment
assigned
benefit
China
clinical trial
control group
coronavirus
Coronavirus disease 2019
COVID-19
COVID-19 patient
critical COVID-19 patient
Critically ill
Critically ill patient
effective
failure
HDIVC
High-dose
high-dose intravenous vitamin C
High-dose vitamin C
hospital
ICU
IL-6
IMPROVE
IMVFD28
Infection
Inflammation
interleukin-6
intravenous
invasive mechanical
medication
no difference
Organ failure
outbreak
outcome
Oxygenation
PaO
paO2/fiO2
Patient
Placebo
Primary outcome
progression
Randomized
Randomly
recruited
reduce
Result
SARS-CoV-2
secondary
severe acute respiratory syndrome coronavirus 2
severe coronavirus disease
severe COVID-19
SOFA
tested
the placebo group
Treatment
treatment period
Trial
two group
Vitamin C
was performed
water for injection
with COVID-19
[DOI] 10.1186/s13613-020-00792-3 PMC 바로가기 [Article Type] Research
[DOI] 10.1186/s13613-020-00792-3 PMC 바로가기 [Article Type] Research
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
코로나19 폐렴으로 입원한 환자의 토실리주맙
Randomized Controlled Trial
[키워드] 95% CI
95% confidence interval
Alaska
antibody
assigned
black
body weight
clinical
coronavirus disease
Coronavirus disease 2019
COVID-19 pneumonia
cumulative
death
died
dose
Efficacy
EMPACTA
ethnic group
Genentech
hazard ratio
Hispanic
Hospitalized
hospitalized patient
hospitalized patients
hyperinflammation
IMPROVE
incidence
Inclusion
intravenously
kilogram
Latino
likelihood
log-rank test
mechanical ventilation
modified intention-to-treat
Native
occurred
outcome
Patient
patients hospitalized
Placebo
placebo group
Pneumonia
Population
populations
Primary outcome
progression
Racial
randomization
Randomly
receive
receiving
receptor
reduced
safety population
Serious Adverse Event
Serious Adverse Events
Site
standard care
survival
the log-rank test
the patient
the placebo group
time-to-event analysis
Tocilizumab
treat
white
[DOI] 10.1056/NEJMoa2030340 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1056/NEJMoa2030340 PMC 바로가기 [Article Type] Randomized Controlled Trial
A structured summary of a study protocol for a multi-center, randomized controlled trial (RCT) of COVID-19 prevention with Kampo medicines (Integrative Management in Japan for Epidemic Disease by prophylactic study: IMJEDI P1 study)
Kampo 의약품을 사용한 COVID-19 예방에 대한 다기관, 무작위 대조 시험(RCT) 연구 프로토콜의 구조화된 요약(예방 연구에 의한 전염병에 대한 일본의 통합 관리: IMJEDI P1 연구)
Letter
[키워드] 1:1
administration
age
allergic
Analysis
appearance
Arm
ARMS
assumed
Asymptomatic
balancing
Blinding
body temperature
calculated
capture
cardiovascular disease
Chain Reaction
clinical
clinical trials
cloud
condition
Control
control group
cough
COVID-19
diabetes
disappearance
dissemination
doctor
dosage
dropout rate
drug
edema
effective
element
Endpoint
exclusion criteria
failure
Fever
Final
final analysis
final analysis)
Frequency
group
hands
healthy
history
hospital
Hospitalization
hypertension
hypokalaemia
Hypothesis
ICU
Immunosuppressant
immunosuppressants
incidence of COVID-19
incidence rate
incidence rates
include
inclusion criteria
Infection
infection rate
Inflammation
interim analysis
interstitial pneumonia
intervention group
investigator
Japan
Japanese
Kampo
Kampo medicines
liver dysfunction
lung
malaise
management
mechanical ventilation
Medicine
number
numbness
objective
observation period
oral administration
oral administration)
outcome
package
parallel-group
participant
Patient
PCR
PCR positive
per day
Period
pharmaceutical
Placebo
placebo group
Placebo tablets
positive result
power
power of 80%
pregnant
Prevent
Prophylactic
prophylactic study
protocol
randomised
Randomized
Randomized controlled trial
RCT
receive
recruited
Registered
Registration
registry
required
Research
respiratory
respiratory diseases
respiratory inflammation
risk factor
Risk factors
Safety
Sample size
SARS-CoV-2 RNA
secondary
Secondary outcomes
Shock
Shortness of breath
significantly
skin rash
sputum
study drug
study period
Study protocol
supplementary material
Symptom
Symptoms
symptoms of COVID-19
Tablet
Taking
Taste
the placebo group
Trial
Trial registration
Two-arm
university
upper respiratory
verification
Viral
viral infection
Vital
website
[DOI] 10.1186/s13063-020-04939-2 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04939-2 PMC 바로가기 [Article Type] Letter
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
비활성화된 SARS-CoV-2 백신 BBIBP-CorV의 안전성 및 면역원성: 무작위, 이중 맹검, 위약 대조, 1/2상 시험
Clinical Trial
[키워드] 95% CI
accelerated
acute respiratory syndrome
Adverse reaction
age
antibody
assigned
BBIBP-CorV
Beijing
Block randomisation
center
China
city
Cohort
concealed
Control
coronavirus
COVID-19 pandemic
creation
District
dose
double-blind
drug
effort
eight
enrolled
Fever
geometric mean titre
greater
group
Group allocation
groups
healthy
humans
Humoral response
IgM/IgG
inactivated
Infectious diseases
investigators
Major
Mild
moderate
neutralising antibody response
neutralising antibody titre
New
Older
outcome assessors
participant
Participants
Placebo
placebo-controlled
plan
post vaccination
prevention
Primary outcome
Program
randomised
Randomly
receive
recipient
recipients
Registered
reported
Safe
Safety
SARS-CoV-2
SARS-CoV-2 vaccine
Science
secondary outcome
separated
Serious Adverse Event
severity
Shangqiu
significantly
stratified
technology
tested
the placebo group
the vaccine
Tolerability
Trial
Vaccine
vaccine candidate
vaccine candidates
[DOI] 10.1016/S1473-3099(20)30831-8 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1016/S1473-3099(20)30831-8 PMC 바로가기 [Article Type] Clinical Trial
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Clinical Trial
[키워드] 1:1
95% CI
95% confidence interval
acute respiratory syndrome
adverse event
age
Analysis
Aside
assigned
authority
baseline
cause
Complication
complications
conducted
coronavirus
coronavirus disease
development
Efficacy
ENCODE
enrolled
Evidence
first dose
full-length spike protein
high risk
incidence
infected with SARS-CoV-2
injection
Injections
Intramuscular injection
Local
mRNA-1273
mRNA-1273 vaccine
mRNA-based vaccine
observer-blinded
occurred
Older
participant
Participants
Person
Phase 3
Placebo
placebo-controlled trial
prefusion
Prevent
primary end point
PROTECT
Randomized
Randomly
reactogenicity
receive
Result
Safety
SARS-CoV-2
SARS-COV-2 infection
Secondary analyses
severe disease
systemic reactions
the placebo group
The United States
Trial
two groups
vaccination
Vaccine
virus
Volunteer
[DOI] 10.1056/NEJMoa2035389 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1056/NEJMoa2035389 PMC 바로가기 [Article Type] Clinical Trial
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
코로나19로 입원한 환자에서 토실리주맙의 효능
Randomized Controlled Trial
[키워드] 95% CI
95% confidence interval
acute respiratory syndrome
analyses
assigned
baseline
benefit
blockade
body temperature
comparison
confidence interval
coronavirus
coronavirus disease
death
disease
double-blind
effective
Efficacy
enrolled
Fever
greater
hazard ratio
Hispanic
hospitalized patient
Hyperinflammatory
Infection
interleukin-6 receptor
intubation
Latino
maintain
mechanical ventilation
median age
median time
men
outcome
oxygen saturation
Patient
performed
Placebo
placebo-controlled trial
Primary outcome
pulmonary infiltrates
Randomized
Randomly
receive
receiving
SARS-CoV-2
serious infection
single dose
standard care
supplemental oxygen
the patient
the placebo group
time-to-event analysis
Tocilizumab
women
worsening
[DOI] 10.1056/NEJMoa2028836 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1056/NEJMoa2028836 PMC 바로가기 [Article Type] Randomized Controlled Trial
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial
Randomized Controlled Trial
[키워드] absolute difference
acute respiratory syndrome
adult outpatient
adverse events
age
assigned
clinical
Clinical deterioration
Clinical efficacy
clinical trial
coronavirus
Coronavirus disease 2019
COVID-19
criteria
cytokine production
decrease
defined
Deterioration
determine
enrolled
excessive immune response
Final
fluvoxamine
Follow-up
greater
Hospitalization
Infection
less
likelihood
mild COVID-19 illness
occurred
outcome
outcome measures
Outpatient
oxygen saturation
participant
Patient
patients treated
Placebo
Pneumonia
Prevent
Primary outcome
randomization
Randomized
randomized trial
Randomly
receive
receptor
regulate
Serious Adverse Event
Severity of disease
Shortness of breath
small sample size
supplemental oxygen
survival
symptom onset
symptomatic
the placebo group
Trial
with COVID-19
women
[DOI] 10.1001/jama.2020.22760 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1001/jama.2020.22760 PMC 바로가기 [Article Type] Randomized Controlled Trial
Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients
Randomized Controlled Trial
[키워드] acute respiratory distress
Anti-inflammatory
approach
ARDS
complications
Concentration
Coronavirus disease 2019
COVID-19
COVID-19 patient
COVID-19 patients
cytokine secretion
Cytokine storm
disorder
Effect
ELISA
evaluated
expression
Gene Expression
Health
healthy control
identify
IL-18
IL-1β
IL-6
IL-6 expression
indicated
Inflammatory cytokine
inflammatory cytokine production
modulate
modulating
modulation
mRNA expression
multi-organ failure
Nano-curcumin.
Patient
PCR
Pneumonia
receiving
recruited
secretion
serum
significant decrease
significantly
supernatant
syndrome
the placebo group
therapy
TNF-α
Treatment
were assessed
[DOI] 10.1016/j.intimp.2020.107088 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1016/j.intimp.2020.107088 PMC 바로가기 [Article Type] Randomized Controlled Trial